SI
JAZZ icon

Sava Infond’s Jazz Pharmaceuticals JAZZ Stock Holding History

Sava Infond’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Hold
4,200
– – 0.07% 106
2026
Q1 		$794K Hold
4,200
– – 0.11% 113
2025
Q4 		$714K Hold
4,200
– – 0.1% 117
2025
Q3 		$554K Hold
4,200
– – 0.08% 122
2025
Q2 		$446K Buy
4,200
+780
+23% +$84.7K 0.07% 125
2025
Q1 		$425K Hold
3,420
– – 0.08% 126
2024
Q4 		$421K Buy
+3,420
New +$403K 0.07% 124

Other funds holding JAZZ

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.17B AUM 36.16% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
BCM
BTC Capital Management Des Moines, Iowa $1.65B AUM 27.85% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Sava Infond's JAZZ Position: Q2 2026 in Review

Sava Infond held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 4,200 shares worth $1.01M. The position accounts for 0.07% of the portfolio, ranked #106.

Sava Infond first reported a position in JAZZ in Q4 2024 and has held it in 7 quarters since. 87 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Sava Infond held 4,200 shares of Jazz Pharmaceuticals worth $1.01M as of Q2 2026.
  • Sava Infond left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
  • Jazz Pharmaceuticals made up 0.07% of Sava Infond's portfolio in Q2 2026, its #106 holding.
  • Sava Infond first reported a position in Jazz Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 87 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Sava Infond's 13F filing for Q2 2026, filed 16 Jul 2026.